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ABSTRACT
We constructed a reporter influenza A/Puerto Rico/8/1934 virus expressing truncated 124aa N-terminal NS1 protein fused to a 
luciferase reporter sequence (NanoLuc) without signal peptide. The reproduction activity of the vector correlated well with the 
luminescent activity in the lysates of infected cell cultures or mouse respiratory organ suspensions. Surprisingly, we found that 
luciferase enzymatic activity was present not only in the intracellular compartments but also in cell culture supernatants as well as 
in the sera or bronchiolar lavages of infected mice. This fact allowed us to formulate a working hypothesis about the extracellular 
delivery mechanism of the NS1 protein. To test this idea, we conducted co-transfection experiments in Vero cells with different 
combinations of plasmids encoding influenza genomic segments and chimeric NS1-NanoLuc encoding plasmid. We found that the 
emergence of the luciferase reporter in the extracellular compartment was promoted by the formation of the ribonucleoprotein 
complex (RNP) from the co-transfection of plasmids expressing PB1, PB2, PA, and NP proteins. Therefore, influenza NS1 protein 
may be delivered to the extracellular compartment together with the nascent RNP complexes during the maturation of virus 
particles.
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Extracellular delivery of NS1 protein
INTRODUCTION
Influenza viruses belong to the family of the Orthomyxo-
viridae. Viruses of this family have a segmented, single-
stranded, negative-sense RNA genome. The influenza 
virus genome comprises eight segments encoding up to 
17 proteins and polypeptides [1].
The envelope of the influenza A virion is formed by 
a lipid membrane derived from the host cell. Two glyco-
proteins hemagglutinin (HA) and neuraminidase (NA) 
are embedded into a lipid bilayer. HA mediates virus at-
tachment and entry; NA helps virions to release from the 
infected cell [2]. HA defines the virus subtype and is a tar-
get for neutralizing antibodies [3]. In addition, the viral 
membrane incorporates the M2 transmembrane protein 
that forms ion channels. The inner surface of the virion 
envelope is formed by the M1 matrix protein [4]. The 
core of the virions is made up of the ribonucleoprotein 
complex (RNP), consisting of viral RNA segments (vRNA) 
coated with nucleoprotein (NP) and associated with RNA 
polymerase complex, which includes the polymerase 
basic protein 1 (PB1), polymerase basic protein 2 (PB2), 
and polymerase acidic protein (PA) [5, 6]. Non-structural 
protein-1 (NS1), nuclear export protein (NS2/NEP) and 
the third protein (NS3) are synthesized from the eighth 
genome segment. [7]. Among non-structural proteins, 
the NS1 protein plays the most significant role due to its 
Extracellular delivery of NS1 protein
mir-journal.org 28  Volume 8    Number 1     2021
ability to bind to RNA species and to antagonize the in-
nate immune system [8, 9].
The infection is initiated by HA attachment to sialic 
acid receptors of the host cell followed by the endocyto-
sis, fusion, and release of the viral RNP into the cytosol 
[4]. The RNP is imported into the nucleus by interact-
ing with the host cell factors importin α/β1. In the nu-
cleoplasm, the complex of RNP and importin dissociates 
[5, 10]. In the nucleus, negative-sense vRNAs are tran-
scribed into mRNAs (incomplete complementary cop-
ies of vRNAs that are capped and polyadenylated) and 
cRNAs (full-length, positive-sense copies of the vRNAs). 
Both processes are carried out by heterotrimeric viral 
RNA-dependent RNA polymerase. The primary tran-
scription of viral mRNAs are carried out by a polymerase 
complex entering the nucleus as a part of the RNP [10]. 
The mRNAs are transported into the cytoplasm where 
the synthesis of viral proteins is initiated on cytosolic 
ribosomes (PB1, PB2, PA, NP, NS1, NEP, and M1) or ribo-
somes associated with the endoplasmic reticulum (mem-
brane proteins HA, NA, and M2) [5]. Then, viral proteins 
are transported to the nucleus (PB2, PB1, PA, NP, M1, and 
NEP) or to the plasma membrane (HA, NA, and M2). For 
cRNAs and vRNAs transcription, newly synthesized poly-
merase proteins PB2, PB1, PA are used. Nascent vRNAs 
are packed by NP protein and combined with the poly-
merase complex to form new RNPs [11].
The vRNP nuclear export is carried out by NEP/NS2 
and M1 proteins and is mediated by the CRM1 receptor 
that recognizes the nuclear export signal (NES). There 
are several hypotheses about the role of M1: 1) M1 medi-
ates interaction between vRNP and factor CRM1 associa-
tion; 2) M1 is required for the release of vRNP from chro-
matin; 3) M1 prevents the reimportation of vRNP into 
the nucleus [10]. One model of vRNP nuclear export sug-
gests that M1 acts as an adapter protein between vRNP 
and NS2 that interacts with CRM1 directly. According to 
another model, NS2 simultaneously interacts with M1, 
the PB1 subunit of the vRNP complex, and CRM1 [10]. 
NP protein can also mediate the nuclear export of vRNP 
through direct interaction with CRM1 [12]. 
After leaving the nucleus, vRNPs accumulate near 
the microtubule-organizing center and are transport-
ed to the plasma membrane by interaction with Rab11 
protein [10, 13]. The budding of a viral particle occurs 
in lipid rafts on the apical surface of the plasma mem-
brane. HA and NA proteins are localized in the raft while 
M2 accumulates at the borders of budding domains [2]. 
The vRNPs are moving to the budding site due to inter-
action with M1, which binds to the cytoplasmic tails of 
HA and NA [14]. The release of the virus from the plasma 
membrane is mediated by M2, promoting viral scission, 
and NA, thereby preventing the virus aggregating on the 
plasma membrane [5].
The role of NS1 protein in the formation of RNPs or 
virus particles is poorly understood. It was shown that 
NS1 can be found in virions affecting the efficiency of 
genome packaging into the virion [15]. The facilitation 
of genome packaging may occur due to NS1 interaction 
with vRNA [16] thereby indicating the involvement of 
NS1 protein into the formation of RNP complex. The 
RNA binding domain is located at the N-terminus of the 
NS1 protein [17]. Since NS1 protein can interact with 
the RNP complex [18], it is possible to assume that both 
of them may be delivered to the cell surface in asso-
ciation. Indirect confirmation of this hypothesis is the 
detection of anti-NS1 antibodies in sera from humans 
with laboratory-confirmed influenza [19]. In addition, it 
was demonstrated that nonstructural antigens are de-
tected on the surfaces of the cells infected with influ-
enza A virus [20]. 
To confirm the hypothesis of NS1 transport to the 
cell surface, we constructed the A/Puerto  Rico/8/1934 
(A/PR/8/1934) influenza virus vector A/PR8-NS124-Luc 
expressing chimeric NS1 protein fused with luciferase 
reporter sequence (NanoLuc) without a signal peptide, 
which replaces the C-terminal part of NS1 [21]. Using 
this vector, we detected the presence of the chimeric NS1 
protein in the extracellular compartments of infected 
cells and in the bronchoalveolar lavage (BAL) and serum 
of mice. Moreover, we showed that this process is medi-




African green monkey kidney Vero cells (ATCC #CCL-81) 
were adapted for growth in OptiPro serum-free medium 
(Gibco, USA) supplemented with 2% GlutaMax (Gibco, 
USA) and used for virus cultivation, titration, and plas-
mid transfection. For a transfection experiment, 10% fe-
tal bovine serum (FBS) (Gibco, USA) was added to the cul-
ture medium. Human lung carcinoma cells A549 (ATCC 
#CCL-185) were cultured in DMEM/F12 medium (Gibco, 
USA) containing 10% FBS. Madin-Darby Canine Kidney 
(MDCK) cells (IRR, #FR-58) were cultured in α-MEM me-
dium (Biolot, Russia) containing 10% FBS.
Plasmids 
The plasmids encoding eight gene segments of the in-
fluenza A/PR/8/1934 (H1N1) virus: PB2, PB1, PA, HA, NP, 
NA, M, and a modified NS gene were constructed based 
on the analog of the pHW2000 vector for reverse genetics 
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[22]. The N-terminal half of NS1 (amino acids 1-124) was 
fused with the heterologous sequence encoding the Na-
noLuc protein through glycine linker. The sequence en-
coding the NEP protein with a splice site remained un-
changed. Nucleotide sequence of NanoLuc protein was 
optimized by modifying the codon frequency and GC 
content.
Laboratory animals 
BALB/с mice were obtained from the Biomedical Science 
Center (Stolbovaya, Russia). All of the experiments were 
conducted according to the guidelines for care and work 
with laboratory animals [23] and were approved by the 
local bioethics committee of the Smorodintsev Research 
Institute of Influenza.
Recombinant virus rescue and determination 
of the virus infectious activity in vitro
To obtain the recombinant influenza A/PR8-NS124-Luc 
(H1N1) virus strain, Vero cells were transfected with 
eight bidirectional plasmids based on the pHW2000 vec-
tor encoding the gene segments PB2, PB1, PA, NP, M, HA, 
NA, and the modified NS of A/PR/8/1934 (H1N1) influen-
za virus. The method was described in detail previously 
[24]. The development of infection was determined by 
the virus cytopathic effect and by the hemagglutination 
reaction of the culture medium with a 0.5% suspension 
of chicken erythrocytes. Viruses were propagated in de-
veloping chicken embryos (CEs).
The infectious activity of the recombinant influenza 
A/PR8-NS124-Luc (H1N1) virus was determined in Vero 
and MDCK cell cultures, and in the CEs. Tenfold dilu-
tions of viral material were prepared in culture medium 
or DPBS and inoculated into cell culture wells or allan-
toic cavity of the CEs, respectively. Cells were incubated 
at 37°С, 5% СО2 for 72 h, and the CEs were incubated 
at 34°С for 48 h. Infectious activity was calculated ac-
cording to the method of Reed and Muench [25] and 
expressed in decimal logarithms of the 50% embryonic 
infectious dose (EID50) or tissue culture infectious dose 
(TCID50).
To control the genetic stability of the heterologous 
insert in the virus NS gene segment, the real-time PCR 
(RT-PCR) was performed. Viral RNA was isolated using 
the RNEasy Mini Kit (Qiagen, USA). For reverse transcrip-
tion, the universal Uni12 primer [26] (Beagle, Russia) 
was used. The amplification of the fragment of the chi-
meric NS gene was performed using special primers and 
AgPath-ID OneStep RT-PCR Reagents (Ambion, Thermo 
Scientific, USA). Electrophoresis in agarose gel and the 
ChemiDoc documentation system (Bio-Rad, USA) were 
used to analyze the results of RT-PCR. 
Immunofluorescence assay for studying the NS1 
protein expression 
For immunofluorescence staining, Vero cells were in-
fected with the A/PR/8/1934, A/PR8-NS124, and А/PR8-
NS124-Luc viruses at a multiplicity of infection (MOI) 
of 1.0 TCID50/cell. Twenty hours after infection, the cells 
were examined for NS antigen by indirect immunofluo-
rescence. The staining procedure was carried out in three 
different ways. In the first set of experiments, cells were 
washed twice with PBS, fixed with 4% paraformaldehyde 
(Sigma, Germany) in PBS for 15 min at room temperature 
(RT), and permeabilized with 0.2% Triton X-100 (Amresco, 
USA) in PBS for 15 min at RT. Then, the cells were incu-
bated with 5% milk (DITOL, Russia) in PBS with the ad-
dition of 0.1% Tween-20 (Serva, EU) overnight at 4°С to 
block the nonspecific binding of the antibodies. The solu-
tion of primary mouse monoclonal antibody 1A11 against 
NS1 protein [27] was diluted 1:500 in blocking buffer and 
incubated with cells overnight at 4°С. The solution of flu-
orescent labeled Goat Anti-Mouse IgG Alexa Fluor® 488 
antibodies (ab150113, Abcam, UK) diluted 1:300 in block-
ing buffer were used as secondary antibodies. Staining 
was performed for one hour at RT. The second immuno-
fluorescence assay method differs from the first method 
in that it does not contain a permeabilization stage. In the 
third method used for the staining of cells, no detergents 
were used. Twenty hours after infection, the cells were 
washed twice with culture medium, incubated for an hour 
with monoclonal antibodies 1A11 (dilution 1:500) at 37°С, 
washed twice with culture medium again, and incubated 
for 1 h with the same fluorescent labeled conjugate (di-
lution 1:300) at 37°С. Before microscopy, the cells were 
washed four times. Fluorescence microscopy pictures were 
obtained using the AXIO Vert A.1 microscope system with 
AxioCam ICc5 (Zeiss, Germany).
Determination of the reporter influenza virus 
luciferase activity in vitro 
Vero and A549 cells were used to study the luminescent 
activity of the reporter virus during the first hours of in-
fection. Monolayer cells were washed twice with DPBS 
before adding the viral inoculum. The virus was added to 
cells at MOI of 0.005 and incubated for 1 h at 37°С and 5% 
CO2. Then, the cells were washed, fresh medium was add-
ed, and the incubation continued. Measurements of lucif-
erase activity were performed at 1, 3, 6, 9, 12, and 24 h after 
the medium change. The supernatant was separated from 
cells, cells were washed with DPBS and frozen. Luciferase 
activity was measured in dark-wall plates using Nano-Glo 
Luciferase Assay System (Promega, USA) and CLARIOstar 
multi-photometer (BMG LABTECH, Germany).
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Measurement of luciferase activity and virus 
replication during infection in mice
BALB/с mice were intranasally (i.n.) infected with 
6  logTCID50/mouse of the A/PR8-NS124-Luc and 
A/PR8-NS124 recombinant viruses. The control group 
was infected with A/PR8-NS124 virus obtained from the 
Virus Collection of the Vector Vaccines Laboratory of the 
Smorodintsev Research Institute of Influenza. At 12, 24, 
and 48 h after infection, four mice from each group were 
sacrificed. Bronchoalveolar lavage (BAL), lung and serum 
samples were collected. Lungs were homogenized and 
tested for the viral load. BAL was tested for viral titer and 
luciferase activity. Sera were tested for luciferase activity 
and for the presence of viral RNA. 
The viral load in mouse organ suspensions was de-
termined by TCID50 assay using MDCK cells. To measure 
the luciferase activity, lung homogenates were mixed 1:1 
with the reaction mix from the Nano-Glo Luciferase As-
say System in a black 96-well plate. Influenza virus RNA 
in the serum of infected mice was determined by RT-PCR. 
RNA was isolated using the RNEasy Mini Kit. RT-PCR 
was performed using the Ag-Path One Step RT-PCR re-
agent kit and Human Influenza Virus RT-PCR Detection 
and Characterization Panel (CDC, Atlanta) primers and 
probes.
Cell transfection with plasmids encoding the 
proteins of influenza A 
Vero cells were grown in OptiPro serum-free me-
dium supplemented with 2% GlutaMax and 10% FBS. 
Cells were electroporated with different combinations 
of bidirectional pHW2000-based plasmids encoding 
A/PR/8/1934 influenza virus gene segments and modi-
fied NS gene segment with NanoLuc reporter insert. 
After transfection, the same medium and supplement 
were used. In the first set of experiments, the cells were 
incubated for 6 h after transfection, washed with DPBS, 
and then incubated for another 18 h. In the second set of 
experiments, the cells were incubated during 24 h after 
transfection, washed with DPBS, and then incubated for 
another 5 h. Supernatants and cell lysates were harvest-
ed for the luciferase activity measurement as described 
hereinabove. The results from the experiments reflect 
the luciferase activity of the protein accumulated in the 
cell supernatant over 18 h and 5 h, respectively. 
Statistical analysis
Data analyses were performed using GraphPad Prism 9.0.0 
(GraphPad Software, USA). The experimental and control 
groups were compared using the one-way or two-way 
ANOVA tests with Bonferroni or Dunnett’s post hoc test; 
the level of significance was assumed to be at p<0.05.
RESULTS
Construction and growth characteristic 
of the luciferase reporter vector 
We generated the A/PR8-NS124-Luc reporter influenza 
A vector expressing a NanoLuc luciferase protein se-
quence fused to the N-terminal part of NS1 protein in 
the backbone of A/PR/8/1934 (H1N1) virus. The Nano-
Luc was chosen as a reporter gene due to its small size 
and the ability to generate brighter luminescence than 
Fig. 1. Schematic representation of the modified NS genomic segment of A/PR8-NS124-Luc virus. (A) The structure of the NS genomic 
segment; (B) the structure of mRNA products encoding truncated NS1 protein fused to the luciferase sequence and NEP protein resulted 
from the natural splicing.
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Firefly or Renilla luciferase [21]. The nucleotide sequence 
coding for NanoLuc was modified by optimizing the GC 
content down to 40% corresponding to influenza A virus 
sequences. It is important to mention that the NanoLuc 
sequence did not include any secretory signals for the ex-
tracellular delivery of the transgene. The gene and pro-
tein maps are shown in Fig. 1.
Luciferase influenza vector A/PR8-NS124-Luc (H1N1) 
was obtained by reverse genetics as described previ-
ously [22]. The reporter vector was further amplified 
in Vero cells and CEs. The obtained recombinant virus 
was characterized by high reproductive activity in CEs 
(8.3±0.3 log10 EID50/ml), Vero cells (7.6±0.6 log10 TCID50/ml), 
and MDCK cells (7.7±0.4  log10  TCID50/ml). The genetic 
stability of the A/PR8-NS124-Luc vector was confirmed 
after 4 passages in Vero cells or CEs (data not shown). 
Emergence of luciferase signal in the cell culture 
supernatants 
The expression of NanoLuc protein was assessed in 
Vero and A549 cells infected with A/PR8-NS124-Luc 
(H1N1) virus at a MOI of 0.005. The luciferase activity 
was measured in the culture supernatants and in cell ly-
sates during 24 h after infection. The results are shown 
in Fig. 2. 
Surprisingly, the bioluminescent signal was detected 
not only in cell lysates but also in the supernatants of the 
infected Vero cells already at 6 h post infection, gradually 
increasing for over 24 h (Fig. 2А). In A549 cells, the lucif-
erase expression kinetics was slower than in Vero cells. 
Nevertheless, the extracellular presence of the luciferase 
reporter was also observed in the supernatants of A549 
at 9 h post infection (Fig. 2B). The extracellular delivery 
of the luciferase reporter was most likely not associated 
with the virus mediated cell destruction. Zhirnov et al. 
previously showed that apoptosis in Vero cells infected 
with influenza virus is delayed [28]. In addition, the dose 
of the virus was too low to destroy cells within several 
hours. Moreover, the cells were also protected by the 10% 
FBS present in the cell culture medium. Therefore, we 
were able to demonstrate that the N-terminal part of the 
NS1 protein was transported outside of the infected cells 
in association with the linked luciferase reporter. 
Detection of NS1 protein inside the cell and on its 
surface
Next, we evaluated the expression of NS1 protein in in-
fected cells by immunofluorescence staining. To confirm 
that the localization of the NS1-reporter complex is not 
associated with the impaired function of truncated NS1 
protein, we performed an immunofluorescence study 
with both the reporter virus and wild type (wt) virus. Vero 
cells were infected with A/PR/8/1934, A/PR8-NS124, and 
A/PR8-NS124-Luc viruses at MOI of 1. The immunofluo-
rescence staining was performed 20 h after infection us-
ing anti-NS1 mouse monoclonal antibody 1A11 [27]. In 
order to distinguish between the intracellular and sur-
face expression of NS1 protein, the immunofluorescence 
staining was done with and without cell permeabiliza-
tion. We detected NS1 protein not only in permeabilized 
cells, but also on the surface of the non-permeabilized 
cells. The results are shown in Fig. 3.
To exclude the possibility of membrane damage by 
Tween 20, immunofluorescence staining was performed 
in living cells without any detergents. Therefore, we de-
tected NS1 antigen not only in permeabilized cells but 
Fig. 2. NanoLuc expression in the culture supernatants and cell lysates of infected Vero (A) and A549 (B) cells. Cells were infected with 
A/PR8-NS124-Luc (H1N1) virus at a MOI of 0.005 and incubated at 37°С for 24 h. The supernatants and the cell lysates were frozen at the 
indicated time points and later examined for luciferase activity. The data of the most representative experiments for Vero and A549 cells 
(from set of two) are presented. Each experiment contained three biological replicates.
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also on the surface of the non-permeabilized cells and 
living cells. This was observed for all of the tested vi-
ruses, including the A/PR/8/1934 virus encoding a fully 
functional NS1 protein.
Presence of the luciferase activity in serum and BAL 
of infected mice
To assess the viral replication and reporter gene expression 
in vivo, we infected mice intranasally  with 6.0 log10TCID50/
mouse of the recombinant A/PR8/NS124-Luc virus. The 
PR8-NS124 virus (empty vector) was used as a control. 
At 12, 24, and 48 h post infection serum, BAL and lungs 
were collected for analysis. The viral load in the lung ho-
mogenates and BAL was estimated by titration in MDCK 
cells. Luciferase activity was assessed in BAL and serum. 
We also checked the presence of viral RNA in serum us-
ing RT-PCR. The results are shown in Fig. 4.
We found that the A/PR8-NS124-Luc reporter vec-
tor and the A/PR8-NS124 empty vector replicate almost 
equally in mouse lungs. We were able to detect a high 
luminescent signal in the BAL already at 12 h after in-
fection with a slight increase at 48 h after infection. In 
addition, we detected the luciferase activity in serum 
at 12, 24, and 48 h after infection. No luciferase activity 
was detected in serum and in BAL of mice infected with 
A/PR8-NS124. To exclude the possibility of viremia with 
virions contaminated with NanoLuc, the RT-PCR test was 
performed for serum samples. For the mice infected with 
Fig. 3. NS1 protein expression in Vero cells infected with the A/PR/8/1934, A/PR/8-NS124, and А/PR/8-NS124-Luc viruses. CC stands for 
cell control. Cells were infected at MOI of 1, incubated for 20 h, and then washed, fixed, and permeabilized (left column) or not permeabi-
lized (middle column); or exposed to in vivo staining (right column). NS1 protein was visualized with 1A11 anti-NS1 monoclonal antibody 
and subsequent staining with secondary antibody labeled with the green fluorescent dye Alexa Fluor 488. Images were taken with a Zeiss 
AXIO Vert A.1 fluorescent microscope.
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the A/PR8/NS124-Luc vector, the viral RNA was only de-
tected in one animal at 48 h post infection, while a lu-
ciferase signal was detected in all of the infected mice. 
Therefore, the emergence of the NS-Luc chimeric protein 
in the serum was not associated with the budding of virus 
particles into the bloodstream of infected mice.
Formation of the RNP complex is essential 
for extracellular transport of NS1-NanoLuc  
chimeric protein
We hypothesized that NanoLuc reporter protein fused to 
truncated NS1 protein may be delivered to the extracellular 
compartment due to the interaction of NS1 with the na-
scent RNPs and their transportation to the cell surface. To 
confirm this hypothesis, we performed transfection exper-
iments in Vero cells using different combinations of plas-
mids expressing influenza A virus proteins together with 
the plasmid encoding chimeric NS1-NanoLuc reporter. It 
should be mentioned here that these plasmids contained 
both PolI and PolII promoters and, therefore, the genomic 
RNA products were also synthesized in the transfected 
cells along with the proteins [22].
We found that the extracellular accumulation of Na-
noLuc reporter in the supernatant of cells during 18  h 
Fig. 4. Presence of the virus and luciferase reporter in the tissues of infected mice. BALB/с mice were infected i.n. with the A/PR8-NS124-Luc 
and A/PR8-NS124 recombinant viruses. Mouse BAL, serum, and lung samples collected at indicated time points. Viral load was measured 
in BAL (A) and lungs homogenates (B). Black circles and gray diamonds represent individual values for each mouse infected with the 
A/PR8-NS124-Luc and A/PR8-NS124, respectively. The red line indicates the limit of detection. Difference between groups was analyzed 
by two-way ANOVA with Bonferroni post hoc test; (ns) stands for not statistically significant. Luciferase activity was measured in BAL 
and serum (C). The data are presented only for mice infected with A/PR8/NS124-Luc virus. The luciferase signal in serum and BAL of mice 
challenged with the PR8-NS124 vector was lower than the detection limit (data not shown). Serum was tested for the presence of influenza 
virus RNA (D). All of the samples with Ct values above the dotted red line (Ctmax=38) are considered positive for influenza A virus. Group 
designations are similar to those described hereinabove.
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was detectable for all of the combinations of plasmids 
used for transfection (Fig. 5A). However, the cells trans-
fected with the NS-Luc encoding plasmid accompanied 
with PB2, PB1, PA, and NP expressing plasmids (full RNP) 
demonstrated 100 times higher extracellular enzymatic 
activity in comparison to cells transfected with just only 
NS-Luc plasmid or its combination with the separate 
components of RNP (NS-Luc+NP; NS-Luc+POL (PB2, 
PB1, PA)). The addition of an M genomic segment encod-
ing plasmid did not improve the extracellular transport 
of the reporter in comparison to NS-Luc+NP+POL trans-
fection. 
Next, we performed a transfection experiment in 
order to measure the effect of extracellular delivery of 
NanoLuc reporter at the late time point after transfec-
tion. Transfected cells were incubated for 24 h, washed 
with fresh medium and incubated for another 5  h be-
fore the assessment of the luciferase activity in the cul-
ture supernatants (Fig. 5B). After transfection with only 
NS-Luc plasmid, no signal was detected. However, the 
Fig. 5. Extracellular delivery of the truncated NS1 protein linked to luciferase reporter transgene. The luciferase activity was measured 
in the supernatant and the cell lysate at 24 h post transfection (A). Striped and gray bars represent the values of luciferase activity in the 
supernatant and cell lysate, respectively. The difference between groups was analyzed using two-way ANOVA with Dunnett’s post hoc test; 
(*) indicates p<0.05, (****) indicates p<0.0001. The extracellular accumulation of NS-Luc protein in the supernatant of transfected cells 
during 5 h of the late period after transfection (B). The difference between groups was analyzed using one-way ANOVA with Dunnett’s post 
hoc test; (****) indicates p<0.0001. The results of the most representative experiment (from set of 5) are presented; for each measurement, 
three biological replicates were used.
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co-expression of proteins representing the RNP had a 
dramatic effect on the extracellular transport of the NS1 
linked luciferase reporter. Interestingly, in this case, the 
co-expression of a complete set of plasmids represent-
ing the entire genome of the influenza virus or a genome 
without the HA and NA gene segments reduced the lu-
ciferase signal in the supernatant. This may be explained 
by the competition of the gene segments for polymerase 
binding during replication. It was shown that the inser-
tion of foreign protein negatively affects the competi-
tiveness of the NS segment [29].
Overall, our results demonstrate that influenza NS1 
protein truncated at its N-terminal half and linked to 
luciferase reporter can be delivered outside of infected 
cells presumably in association with the RNP of influ-
enza virus. This leads to the emergence of an NS1 linked 
reporter in the supernatant of infected cells as well as in 
the serum and in the BAL of infected mice. The mecha-
nism of the NS1 interaction with the RNP complex via 
NS1-RNA association or NS1 binding to RNP proteins re-
mains to be elucidated.
DISCUSSION
We have constructed an influenza luciferase reporter 
vector A/PR8/NS124-Luc based on the A/PR/8/1934 in-
fluenza virus. The NanoLuc protein sequence was fused 
to the N-terminal 124 aa of the NS1 protein. The obtained 
vector was characterized by genetic stability and high re-
production activity in vitro (Vero and A549 cells) and in 
vivo (mouse lungs). Although, the infection of mice with 
A/PR8/NS124-Luc vector was not lethal in contrast to the 
infection with wt A/PR/8/1934 virus (data not shown), the 
level of its replication in the lungs was similar to that of 
A/PR8-NS124 virus carrying an identical NS1 gene with-
out transgene. The RNA binding domain located in the 
N-terminal part of NS1 protein is responsible for the vi-
ral resistance to interferons (IFNs) of type I that deplete 
the viral RNA species as pathogen-associated molecular 
patterns [9]. Since A/PR8-NS124-Luc vector was able to 
replicate in IFN competent A549 cells and in mice, it can 
be concluded that the RNA binding domain function was 
not impaired by the attachment of the luciferase reporter 
sequence. The luciferase enzymatic activity was also not 
impaired by fusing to the truncated NS1 protein. 
The high sensitivity of the luminescence detection 
method allowed us to find the NS1-Luc chimeric protein 
in the supernatant of infected Vero cells as early as 6 h 
after infection with very low MOI (0.005). Under these 
conditions, it is very unlikely that the extracellular ap-
pearance of the NS1-Luc protein was due to the apoptotic 
cell death or the cellular membrane damage. Previously, 
Zhirnov et al. demonstrated that the onset of apoptosis 
in influenza virus infected Vero cells is delayed compared 
to IFN competent cell lines starting at 35 h after infec-
tion with much higher MOI (from 2 to 4) [28]. Therefore, 
we assume that luciferase activity in the medium was the 
result of NS1 protein transportation to the cell surface. 
Our results do not contradict the data obtained by other 
researchers. The expression of the full length NS1 pro-
tein of A/WSN/1933 (H1N1) influenza virus on the cell 
surface was previously described [20]. It is also known 
that the natural influenza infection in animals [30, 31] 
or people [19] may result in the formation of NS1 specific 
antibodies indicating the presentation of this antigen to 
B-lymphocytes in the extracellular compartment. The 
formation of antibodies to NS1 protein may serve as in-
direct evidence of its release from the infected cells. 
Similar to in vitro experiments, we were able to detect 
a luciferase signal in the biological fluids of infected mice 
as early as 12 h after infection. The luciferase activity was 
detected in the BAL and serum of infected mice at least 
for 48 h reflecting the reproduction curve of the virus in 
the lungs. Viral RNA was detected in the blood of only 
one animal at 48 h after infection. This means that NS1-
Luc recombinant protein did not enter biological fluids 
as a part of the progeny virions, but was delivered sepa-
rately or was the result of the cell lysis due to the activity 
of natural killer (NK) cells or other cytotoxic cell subsets. 
It also cannot be completely excluded that the measure-
ment of the luciferase activity provides higher sensitiv-
ity compared to a RT-PCR test. In any case, we were able 
to demonstrate that the NS1 protein linked luciferase 
transgene appears in the extracellular compartments of 
infected animals. How long this effect lasts and whether 
the luciferase activity may be detected outside of the vi-
rus replication period remains to be investigated. 
The mechanism of the NS1 protein release from in-
fected cells is not clearly described yet. It has been dem-
onstrated that NS1 protein may interact with RNP. Robb 
et al. [18] suggested that this interaction is possible 
through protein-protein interaction with nucleoprotein. 
However, they do not deny the possibility of the direct in-
teraction of NS1 with RNA. We put forward a hypothesis 
about the export of the NS1 protein through interaction 
with the RNP complex. Previously, it was shown that the 
NP/RNP complex interacts with cytoskeletal filaments 
[10] for transport to the budding site.
The performed transfection experiments in Vero cells 
with plasmids encoding influenza virus proteins and 
RNAs demonstrated that the release of NS1 protein from 
cells is at least 100 times more intensive when transfec-
tion is performed with plasmids encoding full RNP com-
plex. At the same time, we did not detect such dramatic 
Extracellular delivery of NS1 protein
mir-journal.org 36  Volume 8    Number 1     2021
differences in NS1 protein content in cell lysates. This 
suggests that the formation of an RNP complex is neces-
sary for the export of NS1 protein fused to reporter trans-
gene from a cell. Our results are consistent with those 
obtained previously [18] and suggest the interaction of 
the NS1 protein with the RNP complex. However, the 
interaction of the NS1 protein with the components of 
the polymerase complex requires further study and the 
mechanism of NS1 release is also unclear.
The extracellular release of the influenza NS1 protein 
can be of practical importance. Influenza NS vectors have 
been created in order to generate the immune response 
toward proteins coded by sequences inserted into the 
NS1 open reading frame [32, 33, 34]. Since abundantly 
produced NS1 protein predominantly has cytosolic local-
ization, these vectors are especially good for triggering a 
T-cell immune response. Our current data demonstrate 
that priming the B-cell response may also happen when a 
transgene is linked to the N-terminal part of NS1, which 
allows the delivery of the transgene to the cell surface 
in vitro and to the serum and BAL in vivo. Therefore, in-
fluenza NS vectors are capable of inducing an antibody 
response to the transgene, especially in case of prime-
boost immunizations in mice with vaccine viruses be-
longing to different influenza A subtypes [35]. However, 
the data obtained in a mouse model must be proven in 
large animals or in clinical trials performed with influ-
enza NS vectors.
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